Intensity Therapeutics, Inc.
INTSNASDAQHealthcare● Active
$3.78
+$0.01(+0.27%)
Market Cap$7128917
P/E Ratio—
52W High$43.5
52W Low$3.65
Intensity Therapeutics, Inc. (INTS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INTS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.96
Est. -$1.19 · +19.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
INTS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.87 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$1.19 | -$0.96 | +19.3% | — | — | — |
| ▼ Q1 FY2026 | Mar 27, 2026 | -$1.24 | -$1.69 | -36.3% | — | — | — |
| — Q4 FY2025 | Nov 6, 2025 | -$0.06 | -$0.06 | +0.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.06 | -$0.13 | -116.7% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.21 | -$0.22 | -4.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.23 | -$0.22 | +4.3% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.27 | -$0.25 | +7.4% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.87
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.96
EPS Est.
-$1.19
EPS Surpr.
+19.3%
Revenue
—
Q1 FY2026
Mar 27, 2026Miss
EPS Actual
-$1.69
EPS Est.
-$1.24
EPS Surpr.
-36.3%
Revenue
—
Q4 FY2025
Nov 6, 2025
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.06
EPS Surpr.
-116.7%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.22
EPS Est.
-$0.21
EPS Surpr.
-4.8%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.23
EPS Surpr.
+4.3%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.25
EPS Est.
-$0.27
EPS Surpr.
+7.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $-1.01 | $-1.01 | $-1.01 | 1 |
| Q4 FY2026 | $-0.85 | $-0.85 | $-0.85 | 1 |
| Q3 FY2026 | $-0.84 | $-0.84 | $-0.84 | 2 |
| Q2 FY2026 | $-0.87 | $-0.87 | $-0.87 | 2 |
| Q1 FY2026 | $-1.08 | $-1.08 | $-1.08 | 2 |
| Q4 FY2025 | $-1.35 | $-1.24 | $-1.12 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +19.3% | $5.21 | $5.11 | -1.92% |
| ▼ Q1 FY2026 | Mar 27, 2026 | -36.3% | $6.11 | $6.03 | -1.31% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +0.0% | $14.25 | $12.13 | -14.88% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -116.7% | $6.82 | $6.30 | -7.62% |
| ▼ Q2 FY2025 | May 13, 2025 | -4.8% | $13.45 | $12.94 | -3.79% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +4.3% | $58.50 | $58.25 | -0.43% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +7.4% | $84.75 | $77.50 | -8.55% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -12.5% | $118.50 | $115.50 | -2.53% |
Q2 FY2026-1.92%
Report Date
May 7, 2026
EPS Beat/Miss
+19.3%
Price Before
$5.21
Price After
$5.11
Q1 FY2026-1.31%
Report Date
Mar 27, 2026
EPS Beat/Miss
-36.3%
Price Before
$6.11
Price After
$6.03
Q4 FY2025-14.88%
Report Date
Nov 6, 2025
EPS Beat/Miss
+0.0%
Price Before
$14.25
Price After
$12.13
Q3 FY2025-7.62%
Report Date
Aug 7, 2025
EPS Beat/Miss
-116.7%
Price Before
$6.82
Price After
$6.30
Q2 FY2025-3.79%
Report Date
May 13, 2025
EPS Beat/Miss
-4.8%
Price Before
$13.45
Price After
$12.94
Q1 FY2025-0.43%
Report Date
Mar 13, 2025
EPS Beat/Miss
+4.3%
Price Before
$58.50
Price After
$58.25
Q4 FY2024-8.55%
Report Date
Nov 13, 2024
EPS Beat/Miss
+7.4%
Price Before
$84.75
Price After
$77.50
Q3 FY2024-2.53%
Report Date
Aug 8, 2024
EPS Beat/Miss
-12.5%
Price Before
$118.50
Price After
$115.50
Avg Beat Reaction-6.45%
Avg Miss Reaction-3.81%
Beat Rate4 / 8 quarters
Largest Move-14.88% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INTS ends December
Intensity Therapeutics, Inc. (INTS) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.96 — beating the analyst consensus of $-1.19 by +19.3%. The next INTS earnings date is expected around September 1, 2026.
Each quarter, investors track INTS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INTS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INTS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INTS earnings · 5 questionsIntensity Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. INTS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INTS historically reports after market close (AMC).
INTS earnings datewhen is INTS earningsINTS next earnings datewhen does INTS report earningsINTS earnings calendar
▸ Source: FMP · Intensity Therapeutics, Inc. SEC filings · US GAAP · Intensity Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026